Pilot Clinical Trial - Comparative Study of Two Material Concentration of OD-141309

NCT04703335 | Unknown Early Phase 1 FDA Drug

• 1 other identifier: OD-01-SSI-141309
• Study Type: interventional
• Target: 84
• Locations: 0 countries
• Sites: N/A

Brief Summary

A sufficient number of subjects will be entered into testing to complete 42 subjects per each of the 2 test and 2 control configurations. A total of 84 subjects, testing bi-laterally (168 abdomen and groin sites in total completed, 42 abdomen and groin sites per each test and control material) will be evaluated using the standardized ASTM E1173 test method. Following a 14-day restriction period, subjects will be sampled for baseline, 10 minutes, 6 hours, and 24 hours post application (subjects will not be sequestered) for microbial reduction evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and groin: ≥ 5.0 log10 CFU/cm2.

Conditions

Infectious Disease

Outcome Measures

Primary Outcomes (1)

• Antimicrobial efficacy

  A primary efficacy variable for this study is the immediate antimicrobial effect at 10-minutes post-application of the change on measurement of two-test products against a positive control on the skin flora. The effectiveness criteria are that the log10 recoveries of the two test products (1% and 1.5%) are non-inferior to the Positive Control (2.0% chlorhexidine gluconate) with a 0.5 margin (log10 scale) per square centimeter on the abdominal and inguinal sites within 10 minutes after drying. The determination of non-inferiority will be based on a log10 multiple linear regression model. The Average Treatment Effect (ATE) is the mean difference of the test and the positive control products used in performing a non-inferiority statistic.

  10-minutes

Secondary Outcomes (1)

• Persistence of Antimicrobial Effect

  6-hours

Study Arms (1)

Non-inferiority and Persistence

EXPERIMENTAL

Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution).

Drug: Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation

Interventions

Antimicrobial efficacy of gel ZHCK4 as a patient preoperative skin preparation DRUG

Evaluate the antimicrobial efficacy of two concentrations of one patient preoperative skin preparation product compared to a positive control (2.0% chlorhexidine gluconate) and negative control (physiological saline 0.9% solution). Following a 14-day restriction period, subjects will be sampled for baseline, 10-minutes, 6-hours, and 24-hours microbial reduction evaluations post-product application. Subjects will not be sequestered for the 6-hour or 24-hour evaluations. Test day baseline criteria will be set at: abdomen: ≥ 3.0 log10 CFU/cm2, and inguen: ≥ 5.0 log10 CFU/cm2.

Non-inferiority and Persistence

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects may be of either sex, at least 18 years of age and no more than 65 years of age, and of any race.
• Subjects must be able to read and understand English.
• Subjects must read and sign an Informed Consent Form, List of Restricted Products Form, and Allowed and Restricted Products for Hand Cleaning During Coronavirus Disease 2019 (COVID-19) Pandemic Form prior to participating in the study, as well as have an Authorization to Use and Disclose Protected Health Information Form on file at the testing facility.
• Subjects must be in good general health and have no medical diagnosis of a physical condition, such as a current or recent severe illness, medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an organ transplant, mitral valve prolapse with heart murmur, fibromyalgia, ulcerative colitis, Crohn's disease, asthma, lung disease, liver disease, kidney disease, heart disease, hypertension, an immunocompromised condition such as AIDS (or HIV positive), lupus, medicated multiple sclerosis and must not have a history of smoking or vaping in the past 2 years.
• Subjects will have test sites on the skin of the abdomen and/or inguinal free of injury and in good condition (no active skin rashes, excessive freckling, moles, scratches, breaks in the skin, etc.) and have no currently active skin diseases or skin conditions (for example, contact dermatitis, psoriasis or eczema) that may compromise subject safety or study integrity.
• Subjects must have skin within 6 inches of the test sites that is free of tattoos, dermatoses, abrasions, cuts, lesions or other skin disorders. Subjects with tattoos, scars, active skin rashes, or breaks in the skin of test sites, skin blemishes, such as dry scabs or warts, may be admitted at the discretion of the Principal Investigator, Subinvestigators, or Consulting Physicians.
• Subjects must be able to lay on their backs with one leg bent to expose inguinal test site for approximately 20 minutes

You may not qualify if:

• Known allergies to vinyl, latex (rubber), alcohols, metals, tapes or adhesives, inks, sunscreens, deodorants, laundry detergents, topically applied fragrances, cleansers, or to common antibacterial agents found in soaps or lotions, particularly chlorhexidine gluconate, perillyl alcohol or isopropanol.
• Have experienced hives (raised welts) as a reaction to anything that contacted the skin with the exception of items that cause hives as a reaction to the general population (e.g. poison oak and poison ivy).
• Use of systemic or topical antibiotic medications.
• Use of systemic or topical steroids, other than for contraception, hormone therapy, post-menopausal indications. This includes steroid medications used to treat asthma. Note: topically applied hormonal steroids used for post-menopausal reasons must not get on the test sites.
• Any type of port (or portacath) or Peripherally Inserted Central Catheter (PICC).
• Pregnancy, plans to become pregnant or impregnate a sexual partner within the pre-test and test period of the study, or nursing a child. Female subjects must have a negative urine pregnancy test documented before treatment with test materials.
• Current participation or participation in a clinical study in the 14 days prior to the first lab visit.
• Any medical condition or use of any medications that, in the opinion of the Principal Investigator or Consulting Physicians, would preclude participation.

Sponsors & Collaborators

• Zaycor Healthcare Corp: lead
• BioScience Laboratories, Inc.: collaborator

MeSH Terms

Conditions

Communicable Diseases

Condition Hierarchy (Ancestors)

Infections; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Jose Zayas, PhD

CONTACT

13058984868; jzayas@zaycor.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2021
• First Posted: January 11, 2021
• Study Start: June 1, 2023
• Primary Completion: August 1, 2023
• Study Completion: September 1, 2023
• Last Updated: February 11, 2022

Record last verified: 2022-02